Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Catalent, Inc. Common Stock (NY: CTLT )

63.48 UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalent, Inc. Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Catalent, inc (CTLT) Q4 2021 Earnings Call Transcript
CTLT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Mid-Afternoon Market Update: Affirm Shares Jump Following News Of Amazon Partnership; Adtran Shares Drop
Toward the end of trading Monday, the Dow traded up 0.02% to 35,462.17 while the NASDAQ rose 1.02% to 15,283.07. The S&P also rose, gaining 0.59% to 4,535.90. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Nasdaq Jumps Over 100 Points; Astra Space Shares Plunge
Midway through trading Monday, the Dow traded up 0.10% to 35,490.10 while the NASDAQ rose 0.85% to 15,258.38. The S&P also rose, gaining 0.59% to 4,536.02. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Morning Market Update: Markets Mixed; Catalent To Acquire Bettera
Following the market opening Monday, the Dow traded down 0.13% to 35,408.32 while the NASDAQ rose 0.61% to 15,221.76. The S&P also rose, gaining 0.32% to 4,523.75. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Catalent's Debt Overview
Shares of Catalent (NYSE:CTLT) rose by 23.76% in the past three months. Before having a look at the importance of debt, let us look at how much debt Catalent has. Catalent... 
Via Benzinga
Catalent Makes Strategic Move For Consumer Health Business With Bettera Deal
Catalent Inc (NYSE: CTLT) has reported Q4 sales of $1.19 billion, +25% Y/Y as reported, or 22% in constant currency, edging out analysts' average expectation... 
Via Benzinga
Catalent to Extend Leadership in Rapidly Growing Nutraceuticals Market with Proposed $1 Billion Acquisition of Bettera, a Leading Gummies Manufacturer
From Catalent, Inc.
Via Business Wire
Catalent, Inc. Reports Fourth Quarter Fiscal 2021 Results
From Catalent, Inc.
Via Business Wire
Highlander Partners Announces the Signing of a Definitive Agreement to Sell Bettera Brands to Catalent
From Highlander Partners
Via Business Wire
A Peek Into The Markets: US Stock Futures Edge Higher After S&P 500, Nasdaq Hit Record Highs
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the S&P and the Nasdaq hit record closing highs in the previous session following... 
Via Benzinga
Topics Stocks
Exposures US Equities
5 Stocks To Watch For August 30, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Zoom Video Communications Inc (NASDAQ: ZM) to report quarterly earnings at $1.16 per share on... 
Via Benzinga
Earnings Scheduled For August 30, 2021
Companies Reporting Before The Bell Catalent Inc (NYSE: CTLT) is expected to report quarterly earnings at $1.03 per share on revenue of $1.14 billion. Cloudera, Inc. (NYSE: CLDR... 
Via Benzinga
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
A Look Into Catalent's Price Over Earnings
In the current market session, Catalent Inc. (NYSE:CTLT) is trading at $126.21, after a 0.1% drop. However, over the past month, the stock went up by 8.33%, and in... 
Via Benzinga
EMA Approves Additional Sites To Boost Output Capacity For mRNA-Based COVID-19 Vaccines
European Medical Agency (EMA) has approved additional manufacturing sites for mRNA-based coronavirus vaccines developed by Pfizer Inc (NYSE: PFE) - ... 
Via Benzinga
Exposures COVID-19
Unusual Options Activity Insight: Catalent
On Monday, shares of Catalent (NYSE:CTLT) saw unusual options activity. After the option alert, the stock price moved up to $121.14. Sentiment: BEARISH Option Type: TRADE Trade... 
Via Benzinga
Catalent, Inc. Announces Fourth Quarter Fiscal Year 2021 Earnings Conference Webcast
From Catalent, Inc.
Via Business Wire
Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Based Target Initiative to Reduce Carbon Footprint
From Catalent, Inc.
Via Business Wire
2 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
Catalent Plans $100M Expansion Of Biologics Capabilities At Italian Vaccine Plant
Catalent Inc (NYSE: CTLT) will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing... 
Via Benzinga
Moderna's COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested
Moderna Inc (NASDAQ: MRNA) has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine. The COVID-... 
Via Benzinga
Exposures COVID-19
5 Top ETFs With Exposure To Biogen
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that... 
Via Benzinga
Exposures Product Safety
Catalent, Inc. to Present at the Biopharma CEO Investor Forum
From Catalent, Inc.
Via Business Wire
AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc’s (... 
Via Benzinga
Exposures COVID-19
Catalent, Inc. to Present at the Jefferies Healthcare Conference and the William Blair Growth Stock Conference
From Catalent, Inc.
Via Business Wire
Catalent, Inc. to Present at the UBS Global Healthcare Virtual Conference
From Catalent, Inc.
Via Business Wire
Catalent Publishes Second Annual Corporate Responsibility Report Highlighting Achievements in an Extraordinary Year for the Pharmaceutical Industry
From Catalent, Inc.
Via Business Wire
Catalent Announces Chief Financial Officer Succession
From Catalent, Inc.
Via Business Wire
FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic
The FDA has published a roadmap for working through the backlog of facility inspections built up during the pandemic when it postponed all routine inspections in March... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.